SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--X-37, LLC, an artificial intelligence-enabled drug discovery company, announced today that David Gluckman, M.D., has joined the company’s Board of Directors. Dr. Gluckman is Vice Chairman of Investment Banking and Global Head of Lazard’s Healthcare Group. He has been with Lazard since 1998, providing strategic and financial advice to senior executives and boards of directors at leading healthcare companies globally.
"We welcome Dr. Gluckman to X-37’s Board of Directors and look forward to benefitting from his experience and expertise in corporate strategy and finance as we advance our discovery and development programs against a variety of pharmaceutical targets,” said David Collier, M.D., CEO and cofounder of X-37. “Dr. Gluckman’s network and experience will be very valuable to X-37 as we seek to capitalize on these developments through partnerships with, and acquisitions by, major pharmaceutical companies.”
X-37 identifies high-value drug targets, generates novel drug leads against these targets using Atomwise’s AI platform for structure-based drug design, and develops each of these drug programs to a medically-relevant inflection point, where it can be acquired by or partnered with a major pharmaceutical company to be brought to market. X-37 makes use of an LLC structure permitting each drug development program to be housed in a separate virtual company under the parent LLC. This structure allows X-37 to divest individual drug development programs, while maintaining the parent company and team.
"X-37’s flexible business model allows these successful drug hunters to do what they do best, discover and develop novel drug candidates for important diseases,” said Dr. Gluckman. “I look forward to providing strategic guidance to the X-37 leadership team to help them capitalize their multiple therapeutic opportunities.”
Dr. Gluckman is a member of the Advisory Board of the Vagelos Program in Life Sciences and Management, jointly administered by the College of Arts and Sciences and the Wharton School at the University of Pennsylvania. He is a member of the Board of Trustees of the Hackley School. He is a member of the Leadership Council of AmeriCares and is a Lazard representative in The Council of Foreign Relations, Corporate Leader Program. Prior to joining Lazard, Dr. Gluckman was a practicing physician in Toronto, Canada. Dr. Gluckman is a licentiate of the Medical Council of Canada and a member of the College of Physicians and Surgeons of Ontario.
About X-37
X-37 is a pharmaceutical discovery and development company, which uses advanced artificial intelligence technology from Atomwise, Inc., to screen vast libraries of chemical compounds against high value pharmaceutical targets. X-37 develops these novel drug candidates under an innovative LLC structure which allows the sale or partnership of individual development programs in a simple and efficient manner. The team at X-37 possesses deep expertise in pharmaceutical development and the selection of pharmaceutical targets of high importance. For more information, please visit www.x37.ai.
